Discover Fragile X Syndrome (FXS)- the causes, symptoms, diagnosis, and treatment options. Learn about FXS signs, care tips, and support for better outcomes ...
Harmony also touts late-stage asset EPX-100 (clemizole hydrochloride), which the biotech is running through a pair of phase 3 trials in Dravet syndrome and Lennox-Gastaut Syndrome— both rare forms of ...
Harmony Biosciences has paused a mid-stage trial of ZYN002 in 22q11.2 deletion syndrome after the THC-free cannabinoid drug ...
Nancy Brady has been gratified to see the tool she and colleagues pioneered over a decade ago to measure the growth of ...
Servier is souping up its neurology pipeline with a clinical-stage candidate sourced from U.K. biotech Kaerus Bioscience for a rare genetic disease. The French pharma is offering as much as $450 ...
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company KER-0193, a novel, orally bioavailable small molecule, was granted Orphan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results